The COPERNICUS research study
Learn about this study for adults with non-small cell lung cancer (NSCLC) that has spread.
The COPERNICUS study is evaluating an investigational medication for adults who have been recently diagnosed with non-small cell lung cancer (NSCLC).
If you are eligible, you will receive investigational medication + oral study medication.
Study medication will be given in recurring 28-day cycles.
Study doctors want to learn more about the efficacy and safety of the two investigational medication combinations when they are given to patients with advanced or metastatic NSCLC.
The results of this study may provide more information about investigational medication combinations.
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Statistics show that 85 out of every 100 cases of lung cancer are NSCLC. This type of cancer happens when the cells in the lungs start to grow and divide out of control and form a mass called a tumor.
You will be informed about the investigational medication combination you are receiving before you start the study.
The investigational medication will be given as an injection under the skin. You will receive 4 injections during the first cycle, followed by 1 injection per cycle (once every 4 weeks).
See if you may qualify
Answer the following questions to see if you or someone you know may be eligible to take part in this study.
Please keep in mind:
Even if you believe you meet the eligibility criteria, joining a clinical trial is not guaranteed. Whether you’re referred or able to take part depends on a review by a qualified healthcare professional.
About your information:
With your consent, we will use your answers to help determine whether you may be eligible for this clinical trial. You can withdraw your consent at any time.
Your information may be transferred to countries outside your country of residence, including the United States, which may have different data protection rules.
If you submit any personal information about someone else, you confirm that you have permission to do so.
Please read our Privacy policy for more details.